AGIO · Agios Pharmaceuticals, Inc.
$35.97
-1.00 (-2.70%)
At close · Jul 28
Market Cap
$2.14B
Shares
59.47M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$1,800,000,000
as of 2021-04-02
· total across 2 concurrent programs· not restated in filings since 2024-02-15
Remaining Authorization
$415,500,000
as of 2021-06-30
· not restated in filings since 2021-07-29
Program Utilization
76.9%
$1,384,500,000 used of $1,800,000,000
Concurrent Repurchase Programs
| Authorized | As of | Remaining | Remaining as of | Source |
|---|---|---|---|---|
| $600,000,000 | 2021-04-02 | — | — | 10-K, filed 2024-02-15 |
| $1,200,000,000 | 2021-03-25 | — | — | 10-K, filed 2024-02-15 |
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Quarter Ended | Cash Spent | Source |
|---|---|---|
| 2022-09-30 | $0 Δ | 10-Q, filed 2022-11-03 |
| 2021-09-30 | $254,391,000 Δ | 10-Q, filed 2022-11-03 |
| 2020-09-30 | $0 Δ | 10-Q, filed 2021-11-03 |
Key facts
CIK
1439222
CUSIP
00847X104
13F (30d)
61 filings
37 filers
Visit website
Investor relations